UNSPSC 51182500: Combination antithyroid agents and supplements

This classification denotes combination drugs used to treat hyperthyroidism by reducing the excessive production of thyroid hormones, hence the term ANTITHYROID AGENTS. Typical combination antithyroid agent and supplement constituents are iodine and levothyroxine.

UNSPSC 51182500 Combination antithyroid agents and supplements, a Class code, covers generic and branded pharmaceutical products supplied through multistate cooperative purchasing agreements to state and local government healthcare facilities. State and local governments buying under this code procure pharmaceutical manufacturers' products through established wholesaler networks with negotiated pricing, compliance certification, and supply-chain security requirements. Recent solicitation activity shows this code encompasses not just antithyroid agents but a broader generic multi-source pharmaceutical category, with state procurement offices and purchasing alliances acting as the primary issuing bodies coordinating volumes across participating jurisdictions including state health systems, county health departments, municipal clinics, and other public healthcare providers. Vendors typically must certify compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain relationships with authorized wholesale distributors capable of chargeback processing, and offer flexible pricing models including flat-price, net-price formats, or WAC-minus structures.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products with a response deadline of March 26, 2026. The procurement requires vendors to supply through three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), with awarded contracts becoming effective July 1, 2026 and spanning two years for new vendors with optional extensions. Evaluation is weighted primarily on price competitiveness (75 percent), with additional points for fixed pricing terms (10 percent), administrative compliance (5 percent), EDI capability (5 percent), and acceptance of a 3 percent administrative fee (5 percent). Vendors must carry commercial general liability insurance of $5,000,000 per occurrence and professional liability of $2,000,000, and all products must hold FDA approval with a minimum six-month shelf life from delivery. This activity represents the dominant recent opportunity in the code, with no competing solicitations identified.